邱錄貴，1964年生，籍貫江西，中國醫(yī)學(xué)科學(xué)院血液病醫(yī)院主任醫(yī)師，博士生導(dǎo)師，實驗血液學(xué)國家重點實驗室一級PI，天津市臍帶血造血干細(xì)胞庫醫(yī)學(xué)主任。1985年畢業(yè)于江西醫(yī)學(xué)院，1991年畢業(yè)于中國協(xié)和醫(yī)科大學(xué)，取得醫(yī)學(xué)碩士學(xué)位，同年就職于中國醫(yī)學(xué)科學(xué)院血液病醫(yī)院；1996-1999年應(yīng)邀于美國路易斯維爾大學(xué)進(jìn)行博士后研究工作；2000年晉升為主任醫(yī)師。主要研究方向為淋系腫瘤基礎(chǔ)與精準(zhǔn)干預(yù)策略，是我國淋巴系統(tǒng)腫瘤領(lǐng)域的主要學(xué)科帶頭人之一。

主要研究方向為淋系腫瘤基礎(chǔ)與精準(zhǔn)干預(yù)策略。在多發(fā)性骨髓瘤、淋巴瘤、慢性淋巴細(xì)胞白血病以及成人急性淋巴細(xì)胞白血病的精確診斷和預(yù)后分層基礎(chǔ)上的整體治療方面積累了豐富的經(jīng)驗，在淋巴系統(tǒng)腫瘤的遺傳學(xué)與分子發(fā)病機(jī)制研究方面取得系列重要成果。

久久综合九色欧美综合狠狠_伊人热热久久原色播放WWW_成A人片亚洲日本久久_久久不见久久见免费影院www日本_97久久精品人人做人人爽,又色又爽又黄的视频在线观看,狼群影院视频在线观看高清版,亚洲AV无码精品网站性色,国产乱码久久久久久红粉影视,精品国产乱码久久久久久一区二区,国产精品免费视频网站,国产A级毛片久久久久久精品,一级特黄高清aaaa大片,亚洲中文字幕欧美一区,久久精品国产99久久狂热,黑人巨大精品欧美_黑人巨大精品欧美黑寡妇_黑人巨大精品欧美一区二区_黑人巨大精品欧美一区二区免费_黑人巨大跨种族video_黑人巨大无码中文字幕无码_黑人巨茎大战俄罗斯美女_黑人巨茎大战俄罗斯美女,中文字幕av不卡|亚洲欧美国产另类|天天干在线播放|日韩黄视频|欧美七区|可以免费看毛片的网站|黄色片在线|国产精品96久久久久久

1. Yi S#, Yan Y#, Jin M, Bhattacharya S, Wang Y, Wu Y, Yang L, Gine E, Clot G,Chen L, Yu Y, Zou D, Wang J, Phan AT, Cui R, Li F, Sun Q, Zhai Q, Wang T, Yu Z,Liu L, Liu W, Lyv R, Sui W, Huang W, Xiong W, Wang H, Li C, Xiao Z, Hao M, Wang J, Cheng T, Bea S, Herrera AF, Danilov A, Campo E, Ngo VN, Qiu L*, Wang L*. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J Clin Invest. 2022 Feb 1;132(3):e153283.  (IF: 19.456)

2. Yu Z#, Wei X#, Liu L#, Sun H, Fang T, Wang L, Li Y, Sui W, Wang K, He Y, Zhao Y,Huang W, An G, Meng F, Huang C, Yu T, Anderson KC, Cheng T, Qiu L*, Hao M*.Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in  multiple myeloma. E Bio Medicine. 2022 Apr;78:103950. (IF:11.205)

3. Gang An# , Daobin Zhou , Shu Cheng , Keshu Zhou , Jianyong Li , Jianfeng Zhou , Liping Xie, Jie Jin , Liye Zhong , Lingzhi Yan , Haiyi Guo , Chenmu Du , Jinhua Zhong , Yiling Yu , Binghao Wu , Lugui Qiu* . A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenstr?m Macroglobulinemia. Clin Cancer Res. 2021 Oct 15;27(20):5492-5501. (IF: 12.531)

4. Di Wang# , Jue Wang# , Guang Hu , Wen Wang , Yi Xiao, Haodong Cai , Lijun Jiang , Li Meng , Yongkun Yang , Xiaoxi Zhou , Zhenya Hong , Zheng Yao , Min Xiao, Liting Chen, Xia  Mao , Li Zhu, Jin Wang, Lugui Qiu*, Chunrui Li*, Jianfeng Zhou*. A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2021 May 27;137(21):2890-2901. (IF: 22.133)

5. Yi S#, Yan Y#, Jin M, Xiong W, Yu Z, Yu Y, Cui R, Wang J, Wang Y, Lin Y, Jia Y,Zhang D, Wang T, Lv R, Liu W, Sui W, Huang W, Fu M, Xu Y, Deng S, An G, Zou D,Li Z, Shi J, Xiao Z, Wang J, Cheng T, Gale RP, Wang L*, Qiu L*. High incidence ofMYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia. Leukemia. 2021Aug;35(8):2412-2415. Jan 22. (IF:12.883)

6. Xu Y#, Fulciniti M*, Samur MK, Ho M, Deng S, Liu L, Wen K, Yu T, Chyra Z, Dereibal S, Zhang L, Yao Y, Chakraborty C, Morelli E, Li N, Lopez MA, Perini T, Mu S, An G, Alonso R,Bianchi G, Tai YT, Anderson KC, Qiu L*, Munshi NC*. YWHAE/14-3-3ε expression impacts the protein load contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020，136(4):468-479. (IF:16.509)

7. An G#*, Yan Y#, Xu Y, Mao X, Liu J, Fan H,Wang Q, Du C, Li Z, Yi S, Lv R, Deng S, Sui W, Fu M, Hao M, Huang W, Zou D, Zhao Y, Yuan C, Du X, Wang J, Cheng T, Tai YT, Munshi NC*, Qiu  L*. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia. 2020,34(2):578-588. (IF:11.528)

8. Franqui-Machin R#, Hao M#, Bai H, Gu Z,Zhan X, Habelhah H, Jethava Y, Qiu L*, Frech  I, Tricot G, Zhan F*. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. J Clin Invest. 2018,128(7):2877-2893. (IF:12.87)

9. Qin Y#, Zhang S#, Deng S#, An G, Qin X, Li F, Xu Y, Hao M, Yang Y, Zhou W*, Chang H*, Qiu L*.  Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma. Leukemia. 2017.31(5):123-1135. (IF:11.412)

10. Yi S#, Li Z, Zou D, An G, Cui R, Zhong S, Li H, Xiong W, Li C, Chen W, Liu W, Lv R, Yu Z, Wang H, Xu Y, Zhou K, Ru K, Wang J, Cheng T, Qiu L*. Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia. Genet Med.19(2):182-191. (IF:7.756)